Coronavirus (COVID-19) Update: FDA Holds Advisory Committee Meeting to Discuss Authorization of COVID-19 Vaccine Candidate as Part of Agency's Review of Safety and Effectiveness Data
The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.
- The FDA recognizes that transparency and dialogue are critical to building public confidence in COVID-19 vaccines.
- These data include, but are not limited to clinical trial data, non-clinical data on the development of the vaccine in the lab, and manufacturing data on how the vaccine is made.
- FDA career officials have been reviewing the data and information ahead of the public advisory committee meeting to ensure a robust discussion with the independent experts.
- In this time of great urgency, FDA staff feel the responsibility to move as quickly as possible through the review process.